AR073755A1 - Formulacion oral que comprende 4-[(1r,3s)-6-cloro-3-fenilindan-1-il]-1,2,2-trimetilpiperazina. uso. metodo. - Google Patents

Formulacion oral que comprende 4-[(1r,3s)-6-cloro-3-fenilindan-1-il]-1,2,2-trimetilpiperazina. uso. metodo.

Info

Publication number: AR073755A1
Authority: AR; Argentina
Prior art keywords: disorder; composition; compound; trimethylpiperazine; chloro
Prior art date: 2008-10-03

Application number

ARP090103813A

Other languages

English (en)

Spanish (es)

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-03

Filing date

2009-10-02

Publication date

2010-12-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41217546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073755(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-10-02 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2010-12-01 Publication of AR073755A1 publication Critical patent/AR073755A1/es

Links

239000000203 mixture Substances 0.000 title abstract 4
238000009472 formulation Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
208000020925 Bipolar disease Diseases 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 2
208000007848 Alcoholism Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
208000021465 Brief psychotic disease Diseases 0.000 abstract 1
208000022497 Cocaine-Related disease Diseases 0.000 abstract 1
208000024254 Delusional disease Diseases 0.000 abstract 1
206010013654 Drug abuse Diseases 0.000 abstract 1
206010026749 Mania Diseases 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
208000027089 Parkinsonian disease Diseases 0.000 abstract 1
206010034010 Parkinsonism Diseases 0.000 abstract 1
208000028017 Psychotic disease Diseases 0.000 abstract 1
208000020186 Schizophreniform disease Diseases 0.000 abstract 1
208000019568 Shared Paranoid disease Diseases 0.000 abstract 1
208000028810 Shared psychotic disease Diseases 0.000 abstract 1
206010043903 Tobacco abuse Diseases 0.000 abstract 1
BYPMJBXPNZMNQD-PZJWPPBQSA-N Zicronapine Chemical compound C1C(C)(C)N(C)CCN1[C@H]1C2=CC(Cl)=CC=C2[C@H](C=2C=CC=CC=2)C1 BYPMJBXPNZMNQD-PZJWPPBQSA-N 0.000 abstract 1
206010001584 alcohol abuse Diseases 0.000 abstract 1
208000025746 alcohol use disease Diseases 0.000 abstract 1
239000011230 binding agent Substances 0.000 abstract 1
201000001272 cocaine abuse Diseases 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
229920001531 copovidone Polymers 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
238000012423 maintenance Methods 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
239000003176 neuroleptic agent Substances 0.000 abstract 1
230000000701 neuroleptic effect Effects 0.000 abstract 1
208000002851 paranoid schizophrenia Diseases 0.000 abstract 1
229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
229940069328 povidone Drugs 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
208000019116 sleep disease Diseases 0.000 abstract 1
150000003890 succinate salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

ARP090103813A 2008-10-03 2009-10-02 Formulacion oral que comprende 4-[(1r,3s)-6-cloro-3-fenilindan-1-il]-1,2,2-trimetilpiperazina. uso. metodo. AR073755A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200801392		2008-10-03
DKPA200900591		2009-05-07

Publications (1)

Publication Number	Publication Date
AR073755A1 true AR073755A1 (es)	2010-12-01

Family

ID=41217546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP090103813A AR073755A1 (es)	2008-10-03	2009-10-02	Formulacion oral que comprende 4-[(1r,3s)-6-cloro-3-fenilindan-1-il]-1,2,2-trimetilpiperazina. uso. metodo.

Country Status (16)

Country	Link
US (1)	US20110178094A1 (2)
EP (1)	EP2344163A1 (2)
JP (1)	JP2012504560A (2)
KR (1)	KR20110081176A (2)
CN (1)	CN102170884A (2)
AR (1)	AR073755A1 (2)
AU (1)	AU2009298264A1 (2)
BR (1)	BRPI0919165A2 (2)
CA (1)	CA2732613A1 (2)
CO (1)	CO6321158A2 (2)
EA (1)	EA201170512A1 (2)
IL (1)	IL210235A0 (2)
MX (1)	MX2011001044A (2)
NZ (1)	NZ590897A (2)
WO (1)	WO2010037398A1 (2)
ZA (1)	ZA201102446B (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1558582E (pt)	2003-07-22	2006-05-31	Arena Pharm Inc	Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
EP2508177A1 (en)	2007-12-12	2012-10-10	Glaxo Group Limited	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en)	2008-04-02	2009-10-08	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
EA018927B1 (ru) *	2008-05-07	2013-11-29	Х. Лундбекк А/С	Способ лечения когнитивного расстройства, ассоциированного с шизофренией
WO2010062321A1 (en)	2008-10-28	2010-06-03	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
JO3421B1 (ar) *	2011-06-20	2019-10-20	H Lundbeck As	طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
PL3135656T3 (pl)	2011-06-20	2019-07-31	H. Lundbeck A/S	Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii
WO2016201373A1 (en)	2015-06-12	2016-12-15	Axovant Sciences Ltd.	Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
WO2017011767A2 (en)	2015-07-15	2017-01-19	Axovant Sciences Ltd.	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
EP3873885A1 (en)	2018-10-29	2021-09-08	H. Lundbeck A/S	Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
EP3891134A1 (en)	2018-12-03	2021-10-13	H. Lundbeck A/S	Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4031216A (en) *	1974-08-12	1977-06-21	Knoll A.G. Chemische Fabriken	3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
IE50867B1 (en) *	1980-02-29	1986-08-06	Kefalas As	Indane derivatives
DE3139970A1 (de) *	1981-10-08	1983-04-28	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) *	1987-04-01	1991-06-25	Janssen Pharmaceutica N.V.	4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) *	1989-02-08	1995-11-14	Biochem Pharma Inc.	Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
CA2091204C (en) *	1992-03-11	1997-04-08	Ronald J. Mattson	Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) *	1992-04-28	1992-04-28	Lundbeck & Co As H	1-piperazino-1,2-dihydroindenderivater
CA2132411A1 (en) *	1994-09-19	1996-03-20	Michael Trani	Enzymatic esterification of long-chain racemic acids and alcohols
US6455736B1 (en) *	1994-12-16	2002-09-24	Uop Llc	Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US6410794B1 (en) *	1994-12-16	2002-06-25	Uop Llc	Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US5807897A (en) *	1996-03-01	1998-09-15	Zeneca Limited	Aminotetralin derivative and compositions and method of use thereof
DE69913332T2 (de) *	1998-05-01	2004-05-27	Pfizer Products Inc., Groton	Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie
IN187170B (2) *	2000-01-04	2002-02-23	Sun Pharmaceutical Ind Ltd
IL162666A0 (en) *	2001-12-28	2005-11-20	Teva Pharma	A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
BRPI0413595B8 (pt) *	2003-08-18	2021-05-25	H Lundbeck As	sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto
US20080269248A1 (en) *	2005-02-16	2008-10-30	H. Lundbeck A/S	Tartrate and Malate Salts of Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine
TWI376373B (en) *	2005-02-16	2012-11-11	Lundbeck & Co As H	Crystalline base of a pharmaceutical compound
PE20080422A1 (es) *	2006-08-10	2008-04-28	Cipla Ltd	Composicion solida antirretroviral de administracion oral
EA018927B1 (ru) *	2008-05-07	2013-11-29	Х. Лундбекк А/С	Способ лечения когнитивного расстройства, ассоциированного с шизофренией

2009
- 2009-10-01 AU AU2009298264A patent/AU2009298264A1/en not_active Abandoned
- 2009-10-01 US US13/119,846 patent/US20110178094A1/en not_active Abandoned
- 2009-10-01 CN CN200980139559XA patent/CN102170884A/zh active Pending
- 2009-10-01 EA EA201170512A patent/EA201170512A1/ru unknown
- 2009-10-01 KR KR1020117007586A patent/KR20110081176A/ko not_active Withdrawn
- 2009-10-01 WO PCT/DK2009/050258 patent/WO2010037398A1/en not_active Ceased
- 2009-10-01 JP JP2011529448A patent/JP2012504560A/ja active Pending
- 2009-10-01 MX MX2011001044A patent/MX2011001044A/es active IP Right Grant
- 2009-10-01 NZ NZ590897A patent/NZ590897A/en not_active IP Right Cessation
- 2009-10-01 EP EP09776299A patent/EP2344163A1/en not_active Withdrawn
- 2009-10-01 BR BRPI0919165A patent/BRPI0919165A2/pt not_active Application Discontinuation
- 2009-10-01 CA CA2732613A patent/CA2732613A1/en not_active Abandoned
- 2009-10-02 AR ARP090103813A patent/AR073755A1/es unknown
2010
- 2010-12-23 IL IL210235A patent/IL210235A0/en unknown
2011
- 2011-03-29 CO CO11037985A patent/CO6321158A2/es not_active Application Discontinuation
- 2011-04-01 ZA ZA2011/02446A patent/ZA201102446B/en unknown

Also Published As

Publication number	Publication date
US20110178094A1 (en)	2011-07-21
CN102170884A (zh)	2011-08-31
KR20110081176A (ko)	2011-07-13
NZ590897A (en)	2012-07-27
AU2009298264A1 (en)	2010-04-08
ZA201102446B (en)	2012-07-25
JP2012504560A (ja)	2012-02-23
BRPI0919165A2 (pt)	2015-12-08
EA201170512A1 (ru)	2011-08-30
CO6321158A2 (es)	2011-09-20
MX2011001044A (es)	2011-03-21
EP2344163A1 (en)	2011-07-20
WO2010037398A1 (en)	2010-04-08
IL210235A0 (en)	2011-03-31
CA2732613A1 (en)	2010-04-08

Legal Events

Date	Code	Title	Description
2012-10-25	FB	Suspension of granting procedure

Publication	Publication Date	Title
AR073755A1 (es)	2010-12-01	Formulacion oral que comprende 4-[(1r,3s)-6-cloro-3-fenilindan-1-il]-1,2,2-trimetilpiperazina. uso. metodo.
BR112014012628A2 (pt)	2017-06-13	di-hidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp
MX377802B (es)	2025-03-11	Metodos y composiciones para trastornos del sueño y otros trastornos.
JP2010529118A5 (2)	2011-07-07
AR109816A2 (es)	2019-01-23	Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia bcl-2
CU23808B7 (es)	2012-04-15	Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
AR074471A1 (es)	2011-01-19	Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer
BR112013032122A2 (pt)	2016-12-13	liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
EA201100358A1 (ru)	2011-10-31	Дабигатран для чрескожной хирургической катетеризации сердца
PE20190390A1 (es)	2019-03-13	Formas cristalinas de un inhibidor de tirosina quinasa de bruton
MX2009012279A (es)	2010-02-17	Distribucion de micro y nanoparticulas con plaquetas.
JP2011524850A5 (2)	2012-02-23
BR112015029491A2 (pt)	2017-07-25	derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112014000371A2 (pt)	2017-01-10	derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
CR20140416A (es)	2014-10-31	Formulaciones farmaceuticas novedosas
CL2018001420A1 (es)	2018-09-28	Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
BR112015029401A8 (pt)	2020-03-17	derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
HRP20120144T1 (en)	2012-04-30	Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
AR067328A1 (es)	2009-10-07	Formas amorfas estabilizadas de mesilato de imatinib
BR122019027412B8 (pt)	2021-07-27	composição farmacêutica de liberação sustentada na forma de micropartículas, processo para preparação das ditas micropartículas, e kit de administração
AR063983A1 (es)	2009-03-04	Formulacion de liberacion controlada de agonistas y antagonistas de piperazina -piperidina del receptor 5-ht1a que tienen una disolucion intestinal mejorada
PE20191240A1 (es)	2019-09-16	Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios
PE20150773A1 (es)	2015-05-21	Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
CL2016001707A1 (es)	2017-02-17	Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11).
ECSP13012832A (es)	2013-09-30	Compuestos de pirazol como antagonistas de crth2